Metformin Mechanism Of Action | Detailed Explanation

Do you know the metformin mechanism of action? Metformin has been shown in recent years to have a good cost-effectiveness ratio, drug accessibility, and prospective benefits for malignant tumors, obesity, liver, and cardiovascular diseases—all without raising the risk of hypoglycemia. Does metformin truly have these "miraculous effects" in real life? Let’s explore the secrets of the metformin mechanism of action together.

What is metformin?

Metformin was formally introduced into the clinical treatment of diabetes mellitus in 1957. Due to its favorable efficacy, safety, health economics evidence, cardiovascular protection-related evidence, and multiple extraglycemic effects, metformin is recommended as the primary therapeutic agent in many domestic and international guidelines for hyperglycemic control of type 2 diabetes mellitus (T2DM).

Metformin in combination with other drugs can cause weight loss and hyperinsulinemia in addition to hypoglycemia. Metformin may be more effective than a single dose in patients who do not respond well to certain sulfonylureas, such as those receiving small intestinal glucosidase therapy.

Classification of metformin

Currently, there are two types of typical metformin preparations used in clinics: compound and single. The former includes regular tablets, enteric-coated pills, and extended-release tablets.

1.Regular tablets: These are more provoking to the gastrointestinal tract than the latter as they dissolve fast in the stomach after passage through the oral cavity. Therefore, the patient may also develop nausea, vomiting, and or abreactions as additional complaints in addition to the distension and abdominal pain.

2.Enteric-coated tablets: the medication is coated with an enteric soluble material that will not disintegrate in the stomach when swallowed orally. However, it starts to dissolve and disintegrate when it gets to the tract of the intestines. This means that the drug can be stimulated without any distracting GI side effects noted. Enteric-coated tablets are classified as short-acting medications and should be taken two to three times daily.

3.Extended-release tablets: This form of tablet in the case of a prodrug uses a gel slow-release process; it dissolves and releases the prodrug in variable time intervals and magnitudes. Moreover, the volume of the extended-release tablet rises with water absorption, and slows down, enhancing the rates of the drug’s absorption through the pylorus.

Metformin mechanism of action 

Metformin improves hyperglycemia primarily through three mechanisms: it stimulates the liver exerting its effects by suppressing hepatic gluconeogenesis and the release of glucose, it stimulates peripheral (fat and muscle) affecting glucose by increasing its utilization and enhancing muscle glycogen synthesis and it also affects the intestinal tract by preventing the uptake of glucose by the intestinal wall cells and thus increasing the excretion of glucose into the intestinal lumen by promoting GLP-1.

Metformin's molecular mode of action may involve improving energy metabolism in muscle, fat, and liver by activating adenylate-activated protein kinase (AMPK) through its impact on PEN2, a subunit of γ-secretase.

Metformin mechanism of action in glucose-lowering

Metformin directly affects glucose metabolism rather than promoting the secretion of insulin:

lThrough the activation of adenylate-activated protein kinase (AMPK) and inhibition of the mitochondrial respiratory complex, it decreases hepatic glucose production and inhibits hepatic gluconeogenesis.

lImprove insulin resistance and stimulate insulin binding to receptors to increase insulin sensitivity in peripheral tissues and insulin-mediated glucose uptake and utilization.

lEnhance glucose uptake and use by non-insulin-dependent tissues (e.g., brain, blood cells, renal medulla, intestine, skin, etc.) to promote anaerobic fermentation of sugar.

lPromote glucose excretion to the colon and inhibit intestinal wall cells' absorption of glucose, which raises glucagon-like peptide-1 (GLP-1) levels.

T2DM can be effectively managed by metformin which significantly reduces FBG and PPH. It also has the virtue of stimulating fat synthesis. It moderates blood glucose in healthy people and, in 40% of newly diagnosed diabetes patients, monotherapy can maintain AC for more than three years. Metformin made HbA1c reduced to 0. 7% to 1. Likewise, there was no reduction in risky sexual behavior noted 0%, as shown in the case of the T2DM patients in the cohort study.

Data on almost 5,000 diabetic patients with type 2 diabetes was gathered through prospective research that lasted more than 20 years and was published in 1998. Numerous clinical trials have completely shown the hypoglycemic effect of metformin's mechanism of action.

Conclusion

After reading this article, you may know more about metformin's mechanism of action. Metformin has a good hypoglycemic effect on type 2 diabetes and is commonly used in clinical practice. To prevent postponing the diagnosis and treatment of the illness, patients must still use it in clinical settings under the supervision of their physicians and continuously monitor their blood sugar levels throughout their course of care. The treatment plan must also be modified in response to the results of this blood glucose monitoring.